76 results
424B5
VBIV
VBI Vaccines Inc.
11 Apr 24
Prospectus supplement for primary offering
9:06am
a notification with Innovation, Science & Economic Development Canada. The Investment Canada Act generally prohibits the implementation of a reviewable
8-K
EX-99.1
VBIV
VBI Vaccines Inc.
2 Apr 24
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
8:00am
, supported by a funding contribution from the government’s Strategic Innovation Fund (SIF). Under the new agreement, the remaining CAD$28 million
8-K
VBIV
VBI Vaccines Inc.
2 Apr 24
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
8:00am
Innovation Fund (SIF). A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference
8-K
EX-99.1
qk48ubh
27 Sep 23
Regulation FD Disclosure
7:30am
8-K
EX-99.1
im2rxrv
14 Aug 23
VBI Vaccines Reports Second Quarter 2023 Financial Results
8:00am
424B5
hhwpexrn22oaorc
7 Jul 23
Prospectus supplement for primary offering
5:25pm
424B5
7ei93mb8qne pbf
7 Jul 23
Prospectus supplement for primary offering
5:20pm
424B5
3t66e5s
5 Jul 23
Prospectus supplement for primary offering
4:31pm
8-K
EX-99.1
4vt7ci824 rutogslp
6 Dec 22
Entry into a Material Definitive Agreement
9:25am
8-K
EX-99.1
7fi7abde1kxosfj
29 Sep 22
VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901
8:00am
8-K
EX-99.1
wmc7i
8 Aug 22
VBI Vaccines Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8:01am
8-K
EX-99.1
2vj8g7fd1uzin6h6bnw4
12 Jul 22
VBI Vaccines Announces Appointment of John Dillman as Chief Commercial Officer
8:00am